Mahadeo, K. M., Baiocchi, R., Beitinjaneh, A., Chaganti, S., Choquet, S., Dierickx, D., Dinavahi, R., Duan, X., Gamelin, L., Ghobadi, A., Guzman-Becerra, N., Joshi, M., Mehta, A., Navarro, W. H., Nikiforow, S., O’Reilly, R. J., Reshef, R., Ruiz, F., Spindler, T., & Prockop, S. (2024). Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein–Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial. The Lancet Oncology, 25(3), 376–387. https://doi.org/10.1016/s1470-2045(23)00649-6